Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
2003 · Advances in experimental medicine and biology · 216 citations
https://doi.org/10.1007/978-1-4615-0081-0_21
P
Pere Gascón
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
316
Papers
13.5K
Citations
47
h-index
115
i10-index
Pere Gascón is an academic researcher from Instituto de Investigación de Enfermedades Raras. The author has contributed to research in topics: Erythropoietin and Anemia Treatment & Neutropenia and Cancer Infections & Biosimilars and Bioanalytical Methods. The author has an h-index of 47, co-authored 269 publications.
Papers by this author
worksDifferential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
2006 · Molecular Cancer Therapeutics · 106 citations
https://doi.org/10.1158/1535-7163.mct-05-0147
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2019 · Clinical Cancer Research · 106 citations
https://doi.org/10.1158/1078-0432.ccr-19-0353
MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence
2021 · Cancer Letters · 57 citations
https://doi.org/10.1016/j.canlet.2021.01.028
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
2008 · British Journal of Cancer · 49 citations
https://doi.org/10.1038/sj.bjc.6604347
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
2020 · BioDrugs · 30 citations
https://doi.org/10.1007/s40259-020-00411-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat